CardioExchange Archive

April 15th, 2014

Case: Assessment of Cardiac Risk and Need for Preventive Medications

Seth Shay Martin, MD and James Fang, MD

A 68-year-old white woman with a history of obesity and depression is seen for cardiac risk assessment. The quality of her diet varies greatly, and she admits to many dietary indiscretions. She has tried several different diets, including low-carbohydrate/high-fat diets. She does not use the treadmill or stationary bicycle in her house or routinely exercise […]

---

April 14th, 2014

Selections from Richard Lehman’s Literature Review: April 14th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include TOPCAT, fibrinolysis for those with intermediate-risk PE, and more.

---

March 30th, 2014

Stage Set for Phase IV Trials of PCSK9 Inhibition

Seth Shay Martin, MD

Seth Martin, a fellow blogging at ACC.14, discusses some exciting developments taking place at the conference.

---

February 17th, 2014

Another Satellite of JUPITER: Lipoprotein(a)

Amit Khera, MD

Amit V. Khera discusses his study group’s analysis of lipoprotein(a) concentrations and residual vascular risk among participants in the placebo-controlled JUPITER trial of rosuvastatin.

---

December 13th, 2013

Dispatch From the Wild Frontier of the Statin Wars

Larry Husten, PHD

The long simmering controversy over the relative benefits and harms of statins has heated to a high boil with the release of the new AHA/ACC U.S. guidelines. But nowhere is the battle more intense right now than in Australia, where, according to the National Heart Foundation, a TV show may be the cause of 2,000 heart attacks […]

---

November 12th, 2013

After Long Wait, Updated U.S. Cardiovascular Guidelines Now Emphasize Risk Instead of Targets

Larry Husten, PHD

Updated cardiovascular health guidelines were released today by  the American Heart Association (AHA) and the American College of Cardiology (ACC). The guidelines are designed to provide primary care physicians with evidence-based expert guidance on cholesterol, obesity, risk assessment, and healthy lifestyle. The new guidelines reinforce many of the same messages from previous guidelines, but also represent […]

---

October 10th, 2013

Prevalence of Cardiovascular Disease Likely to Increase Despite Gains in Treatment

Larry Husten, PHD

It is the best of times and the worst of times in the battle against cardiovascular disease. On the one hand, mortality rates from cardiovascular disease in the U.S. have dropped by more than half in the last 30 years, likely due in large part to improvements in treatment for elevated blood pressure and cholesterol […]

---

August 14th, 2013

Advanced Lipoprotein Analysis: Time for Widespread Implementation?

Behnood Bikdeli, M.D.

Will advanced lipoprotein analysis add real value to patients’ lives?

---

August 9th, 2013

The Guidelines are Dead. Long Live the Guidelines.

Larry Husten, PHD

Following the recent surprising announcement that the National Heart, Lung, and Blood Institute would no longer issue guidelines, leaders of the American Heart Association (AHA) and the American College of Cardiology (ACC) have now announced that are “officially assuming the joint governance, management and public distribution” of the enormously influential cardiovascular prevention guidelines, including the much-delayed and much-anticipated hypertension […]

---

June 20th, 2013

Hypertension and Cholesterol Guidelines Delayed Again as NHLBI Gets Out of the Guidelines Business

Larry Husten, PHD

The National Heart, Lung and Blood Institute (NHLBI) will no longer issue guidelines, including the much-delayed and much-anticipated hypertension (JNC 8) and cholesterol (ATP 4) guidelines. Instead, the NHLBI will perform systematic evidence reviews that other organizations, including the American Heart Association and the American College of Cardiology, will use as a resource for their own guidelines. The […]

---